admin – Page 4162 – Get News Story

Top Companies in Clinical Informatics Market: UnitedHealth Group (US) and Koninklijke Philips N.V. (Netherlands) are the Leading Players

“UnitedHealth Group, one of the world’s largest healthcare companies, has revenue of about USD 372 billion for the year 2023. Optum (Part of UnitedHealth Group) a health services company, completed a merger with Change Healthcare in October 2022 of a USD 7.8 billion”

The global clinical informatics market, valued at US$198.33 billion in 2023, is forecasted to grow at a robust CAGR of 16.0%, reaching US$231.45 billion in 2024 and an impressive US$563.18 billion by 2030. Advanced technologies in healthcare are growing due to the increasing use of such technologies, and AI and big data are very important in that regard. The increasing use of digital tools in healthcare, such as data from medical devices, electronic health records, and billing information, is creating vast amounts of data that AI can study to make things better and faster. Such government actions, such as President Biden’s order in October 2023 to create guidelines for AI in healthcare, are supporting new ideas and helping to develop a skilled workforce. AI tools are also crucial in handling disease outbreaks. The World Health Organization uses AI to make early warning systems and epidemic predictions better, which helps improve healthcare decisions.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=159545339

The Clinical Informatics market is dominated by key players. The major players operating in this market are, UnitedHealth Group (US), Koninklijke Philips N.V. (Netherlands), GE HealthCare (US), Cognizant (US), Oracle (US), Epic Systems Corporation. (US), ExlService Holdings, Inc. (US), EClinicalWorks (US), Medical Information Technology, Inc. (US), Siemens Healthineers (Germany), TruBridge. (US), Veradigm (US), AdvancedMD (US), athenahealth, Inc. (US), Merative (US), NVIDIA Corporation (US), AGFA HealthCare (Belgium), NXGN Management LLC (US), InterSystems Corporation (US), McKesson Corporation (US), Dedalus S.p.A. (Italy), IQVIA (US), SAS Institute Inc. (US), Wipro (India), Health Catalyst. (US), Tempus (US), Practice Fusion, Inc. (US), MedeAnalytics, Inc. (US), Medecision (US), Chartis (US), Allara Health (US), Surgical Information Systems (Georgia), Anumana, Inc. (US), Memora Health Inc. (US), and MediView XR, Inc. (US).

UnitedHealth Group.

UnitedHealth Group, one of the world’s largest healthcare companies, has revenue of about USD 372 billion for the year 2023. Optum (Part of UnitedHealth Group) a health services company, completed a merger with Change Healthcare in October 2022 of a USD 7.8 billion. which gives them access to data from millions of healthcare transactions and boosts their clinical capabilities for the US population. Now the company operates through four business segments: Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare. It offers healthcare products and insurance services and caters to various healthcare providers, such as hospitals, doctors, pharmacies, health plan organizations, and life science companies. The company brought over 900,000 new patients into their value-based care, health benefits, health tech, financial services, and pharmacy services in 2023 only. They care for more than 62 million people through private and government-run health programs and handle more than USD 500 million in annual payments.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=159545339

Koninklijke Philips N.V.

Koninklijke Philips N.V. (Royal Philips) is the parent company of the Philips Group. The company works in four areas: Personal Health, Diagnosis & Treatment, Connected Care, and Others. The company aims to grow in both natural ways and by buying other businesses to increase its market presence. Strategic partnerships in high-potential markets and collaborations have been Philips’ key growth strategy over the years. For example, in November 2023, Philips and NYU Langone Health partnered to focus on patient safety and outcomes. The collaboration integrated innovative health technologies, including digital pathology, clinical informatics, and AI-enabled diagnostics, enabling real-time collaboration among clinicians. Philips has developed partnerships with many large healthcare companies and promising AI start-ups in the healthcare industry, spread across various geographies. In October 2023, Philips collaborated with the World Stroke Organization (WSO) to prevent, treat, and rehabilitate strokes. It emphasized awareness, education, and advocacy. Among its significant subsidiaries are Philips Oral Healthcare, LLC (US), Philips GmbH (Germany), Philips Ultrasound, Inc. (US), and Philips Consumer Lifestyle B.V. (Netherlands).

GE Healthcare

GE HealthCare is a global medical technology, pharmaceutical diagnostics, and digital solutions innovator. The company’s products, solutions, and services span the continuum of patient care, including screening, diagnosis, treatment, and monitoring. Its customers include healthcare providers and researchers, including public, private, and academic institutions. It sells to a global sales team as well as its network of partners and distributors and other third-party companies. By the end of January 2023, GE completed the separation of HealthCare as an independent company capable of issuing stock in the public markets. The company operates in more than 170 countries across the Americas, Europe, Asia, and the Middle East & Africa. Its subsidiaries include Dynamic Imaging, LLC (US), Whatman plc (UK), Image Diagnostic International GmbH (Germany), Clarient, Inc. (US), Thomas Medical Products, Inc. (US), Orbotech Medical Solutions Ltd. (Israel), and Biacore International AB (Sweden). The company serves customers in over 160 countries, conducts R&D in 18 countries, and manufactures its products in 20 countries worldwide. The company has a geographical presence in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.

For more information, Inquire Now!

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/clinical-informatics-market-159545339.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Companies in Clinical Informatics Market: UnitedHealth Group (US) and Koninklijke Philips N.V. (Netherlands) are the Leading Players

AI in Oncology Market worth $11.52 billion by 2030

“Siemens Healthineers is one of the leading healthcare companies globally that help healthcare provider worldwide to offer affordable high-quality care of patients.”

The global AI in oncology market, valued at US$1.92 billion in 2023, is forecasted to grow at a robust CAGR of 29.4%, reaching US$2.45 billion in 2024 and an impressive US$11.52 billion by 2030. This growth can be primarily attributed to rising investments in pharmaceutical and biotech companies to develop potential and advance cancer drugs to reduce the global cancer burden. AI streamlines drug discovery and development processes by offering predictive modeling, simulation, and advanced data analytics, making it easier to evaluate a drug’s safety and efficacy. This reduces drug discovery time and costs as it helps the user minimize the experimental work and optimize the clinical trial design.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=256715534

The major players in the AI in oncology market with a significant global presence are Siemens Healthineers (Germany), GE Healthcare (US), ConcertAI (US), Medtronic (Ireland), F. Hoffmann-La Roche Ltd (Switzerland), Oracle(US), NVIDIA Corporation(US), Koninklijke Philips N.V. (Netherlands), PathAI, Inc. (US), CureMetrix, Inc. (US), Mindpeak GmbH (Germany), Paige AI, Inc. (US), Predictive Oncology (US), Exscientia (UK), Insilico Medicine (US), Iktos (Paris), Tempus (US), Azra AI (US), CureMatch, Inc. (US), OncoLens (US), Triomics (US), Clinakos. (US), Perthera, Inc (US), Cellworks Group, Inc. (US), and biomy, Inc. (Japan). The market players have adopted strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals to strengthen their position in the biosimulation market. The product and technology innovations have helped the market players expand globally by enhancing treatment efficacy, improving patient outcomes, and addressing unmet medical need.

Siemens Healthineers

Siemens Healthineers is one of the leading healthcare companies globally that help healthcare provider worldwide to offer affordable high-quality care of patients. With a track record of 120 years, the company is consistently delivering groundbreaking solutions and offers diverse range of portfolio, including laboratory diagnostics, medical imaging, healthcare IT, therapeutic and molecular diagnostics, and consulting services. Further, Siemens Healthineers is supporting the AI use in healthcare, particularly in cancer care for early detection, diagnosis, and therapy planning. Recently, the company developed AI-Rad Companion and Ethos Therapy that provides automated support in imaging, therapy planning, and adaptive treatments, reducing diagnosis time and enhancing treatment quality.

Further, the company has global footprint with a strong local presence, supported by over 600,000 installed systems and more than 4,400 collaborations worldwide with 46,000 employees worldwide, ensuring timely and efficient services.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=256715534

GE Healthcare

GE HealthCare specializes in medical technology, digital solutions, and care innovations, at a global level supporting over 1 billion patients annually and operating in more than 160 countries. The company offers comprehensive portfolio including monitoring devices, intelligent devices, and imaging diagnostics with more than 200 imaging software applications. GE HealthCare is supporting the use of AI to enhance cancer care. For instance, company’s AI- driven initiatives such as the Health Companion project and AI Innovation Lab, help in aiding personalized treatment planning. The company also supports AI tools for breast cancer recurrence prediction, maternal care advancements, and multimodal X-ray diagnostics. Moreover, GE Healthcare has over 80 FDA-approved AI devices.

Medtronic

Medtronic is one of the major players in the medical devices and therapies market with more than 95,000 employees and presence in over 150 countries. The company helps to alleviate pain, extend life, and restore health by offering diverse solutions portfolio including diabetes care, cardiac and vascular care, minimally invasive therapies, surgical innovations, and spine and neurological treatments. Medtronic highly supports the use of AI in cancer care for early detection and diagnosis. For instance, in order to improve colorectal cancer detection the company launched GI Genius intelligent that helps to identify polyps in real-time during colonoscopy procedures.

North America secured the largest share of the AI in Oncology Market

North America accounted for the largest share of the AI in oncology market. The region’s dominance can be primarily attributed to the significant presence of companies providing AI in oncology solutions, particularly in the US. Major US-based companies include GE Healthcare, ConcertAI, Oracle, NVIDIA Corporation, Predictive Oncology, PathAI, and CureMatrix. The North American AI in oncology market is further driven by ongoing advancements in machine learning and deep learning, rising accessibility of healthcare data, and increasing demand for precision medicine. Collaborations between tech firms and healthcare providers, along with established reimbursement policies, also enhance the integration of AI for cancer diagnostics, treatment planning, and precision medicine. For instance, in April 2024, Moffitt Cancer Center partnered with NVIDIA, Oracle, and Deloitte to reimagine cancer care using advanced AI and machine learning. In March 2024, NVIDIA collaborated with GE HealthCare to advance AI innovations with healthcare-specific foundation models powered by NVIDIA. Additionally, the region is home to several growing start-ups, such as CureMatch, Inc., Azra AI, and Triomics, that are driving innovation through AI-based oncology. These factors collectively position North America as a leading market in the field.

Recent Developments of AI in Oncology Market

In October 2024, GE HealthCare (US) launched its new cloud-first application, CareIntellect for Oncology. This application combines multi-modal patient data from various systems into a unified view, leveraging generative AI to summarize clinical notes and reports.

In September 2024, F. Hoffmann-La Roche Ltd. (Switzerland) collaborated with Qritive (Singapore) to enhance cancer diagnostics and treatment and the adoption of AI among pathologists. This collaboration will enable Qritive’s AI-powered solutions to be fully integrated with Roche’s Navify Digital Pathology platform, which will help pathologists diagnose cancer more accurately and efficiently.

In September 2024, Oracle (US) partnered with Imagene AI Ltd. (US) to introduce CanvOI, an advanced pan-cancer foundation model aimed at supporting innovative research and development in digital pathology and oncology.

In June 2024, ConcertAI (US) collaborated with NVIDIA Corporation (US) to enhance translational and clinical development solutions within its CARA AI platform. ConcertAI will leverage NVIDIA’s AI expertise and infrastructure, including the Meta Llama 3 NIM, to enhance oncology research and treatment through advanced LLM workloads.

In June 2024, Predictive Oncology (US) launched a unique 3D cell culture model to advance cancer drug discovery, offering more accurate in vivo testing and better predictions for clinical outcomes and drug candidate selection.

In May 2024, ConcertAI (US) launched CARA AI, a platform that integrates multi-modal data management, predictive AI, and generative AI to streamline and enhance healthcare processes. The platform supports life sciences and healthcare professionals in exploring multi-modal real-world data (RWD) while utilizing AI-driven workflows.

For more information, Inquire Now!

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AI in Oncology Market worth $11.52 billion by 2030

Africa-centric Company Launches A Crowdfunding Campaign to Help Transform African Trade Starting with Sustainable Agriculture

The African Trade Group (ATG), an Africa-centric company focused on improving trade across the continent, has launched a transformative Indiegogo campaign aimed at bolstering Africa’s manufacturing and export capacity. Led by renowned African trade expert John Akhile, the organization seeks to reshape the economic landscape of Africa, beginning with a sustainable pilot farm project in Congo.

A Mission to Reduce Poverty and Foster Self-Reliance

Despite abundant natural resources, Africa remains the world’s poorest continent. ATG contends that this situation is not destiny but rather a solvable challenge. By using advanced farming practices to produce a key staple—corn—ATG aims to reduce the continent’s reliance on costly imports and divert much-needed currency back into local economies. The pilot farm in Congo will serve as a blueprint for future developments in agriculture and other industries across the region.

The Pilot Farm Project in Congo

The pilot farm project is designed to demonstrate how African countries can turn resource wealth into real economic growth through modern, sustainable agricultural methods. Specifically, the project will:

Reduce Import Reliance: Local corn production will slash costs associated with importing this staple crop, allowing African nations to invest resources elsewhere.
Create Jobs and Stimulate the Local Economy: By training and employing local workers, the pilot farm will help stabilize incomes and support entire communities.
Ensure Sustainable Development: ATG will utilize American farming techniques that balance high productivity with environmental stewardship, setting the stage for long-term viability.

Why Support Matters

ATG is seeking $250,000 in flexible funding to establish this inaugural farm. The organization believes that even modest contributions can jumpstart a long-term transformation, impacting thousands—if not millions—of lives throughout Africa. Once the pilot farm proves successful, ATG envisions expanding the model across the continent, focusing not just on agriculture but also on the development of local industries to create a ripple effect in manufacturing, trade, and exports.

Rewards for Indiegogo Backers

In appreciation of donor support, ATG offers tiered perks corresponding to contribution levels:

$50 Contribution: A signed, framed ‘thank-you’ letter.
$100 Contribution: A commemorative ‘thank-you’ plaque.
$250 Contribution: A signed copy of John Akhile’s book, Unleashed—A New Paradigm of African Trade with the World, plus a ‘thank-you’ plaque.
$500 Contribution: Custom-made gifts from Congo, a signed copy of the book, and a ‘thank-you’ plaque.
$1,000 Contribution: A personal invitation to visit the farm once operational, along with all the above rewards.
$2,000 Contribution: A personalized tour of the farm and meetings with senior government officials, in addition to all the above rewards.

By signing up at African Trade Group’s Crowdfunding Page, supporters can also secure a 15% discount on all perk levels.

How to Help

1.Contribute: Visit the Indiegogo Campaign Page to select a perk that best reflects the desired level of support.

2. Share: Spread the word on social media, with friends, and within local communities. The broader the outreach, the greater the potential impact.

3.Stay Connected: Sign up at the African Trade Group website to receive regular updates about the project’s milestones, success stories, and future expansion plans.

A Step Toward a New Africa in Trade

By backing this campaign, donors are joining ATG in ushering in a new era where African nations are not just importers but also thriving manufacturers and exporters. According to ATG, breaking the cycle of poverty and unemployment begins with crucial steps like this pilot farm—a model that can be replicated throughout the continent to catalyze broad-based economic growth.

To extend the support visit: https://www.indiegogo.com/project/preview/739c8c69

About African Trade Group

African Trade Group is an Africa-centric enterprise dedicated to transforming trade on the continent. Specializing in developing industrial projects and supplying commodities in global markets, ATG partners with stakeholders to strengthen African economies from within. Based in Durham, United States, the organization is committed to fostering local ownership, enterprise, and sustainability in all its initiatives.

For more information, please visit https://africantradegroup.net/crowd-funding/Or contact at info@africantradegroup.net

Media Contact
Company Name: African Trade Group, LLC.
Contact Person: Media Relations
Email: Send Email
City: Durham
Country: United States
Website: https://africantradegroup.net/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Africa-centric Company Launches A Crowdfunding Campaign to Help Transform African Trade Starting with Sustainable Agriculture

Ischemia Reperfusion Injury Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight

“Ischemia Reperfusion Injury Treatment Market”

Ischemia Reperfusion Injury Companies are Pfizer, GNT Pharma, United Therapeutics, GlaxoSmithKline, ICON Clinical Research, Dompé Farmaceutici, Medicure, and others.

(Albany, USA) DelveInsight’s “Ischemia Reperfusion Injury Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ischemia Reperfusion Injury, historical and forecasted epidemiology as well as the Ischemia Reperfusion Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Ischemia Reperfusion Injury market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Ischemia Reperfusion Injury market dynamics.

Request for sample report @ Ischemia Reperfusion Injury Market Forecast

Some of the key facts of the Ischemia Reperfusion Injury Market Report

The Ischemia Reperfusion Injury market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
The tissue damage that happens once the blood flow returns to the tissue following a period of oxygen deprivation is known as ischemia-reperfusion injury (IRI). IHD, which affects 128 million people worldwide, is the primary cause of morbidity.
In the United States alone, ischemic injury incidence from myocardial infarction, stroke, and other thrombotic events affects more than 1.3 million people annually.
Ischemic heart disease, which leads to acute myocardial infarction and heart failure, is responsible for over 9 million preventable deaths each year.
Key Ischemia Reperfusion Injury Companies: Pfizer, GNT Pharma, United Therapeutics, GlaxoSmithKline, ICON Clinical Research, Dompé Farmaceutici, Medicure, and others
Key Ischemia-Reperfusion Injury Therapies: atorvastatin, Neu2000KWL group, Treprostinil, rosiglitazone, Bendavia (MTP-131), Reparixin, (MC-1) Pyridoxal 5′-phosphate, and others
The Ischemia Reperfusion Injury epidemiology based on gender analyzed that Males have a higher prevalence of Ischemia Reperfusion Injury than females. Most primary causes of IRI, including stroke, thrombosis, and others, affect males more than females due to various factors

Ischemia Reperfusion Injury Overview

Ischemia-reperfusion (I/R) injury occurs when blood supply returns to a tissue after a period of ischemia (lack of oxygen), leading to further cellular damage. This paradoxical injury results from a surge of reactive oxygen species (ROS), inflammation, and calcium overload, causing oxidative stress, endothelial dysfunction, and apoptosis. I/R injury commonly affects vital organs such as the heart (myocardial infarction), brain (stroke), kidneys, liver, and intestines.

The Ischemia Reperfusion Injury pathophysiology involves an initial ischemic phase, where oxygen deprivation disrupts ATP production, followed by the reperfusion phase, which triggers an inflammatory cascade and mitochondrial dysfunction. Key contributors include neutrophil activation, cytokine release, and impaired nitric oxide signaling, leading to vascular damage and tissue necrosis.

Ischemia Reperfusion Injury Management strategies focus on minimizing oxidative stress and inflammation. Therapies include ischemic preconditioning, antioxidants, anti-inflammatory agents, and controlled reperfusion techniques. In cardiac and stroke patients, timely interventions such as thrombolysis, percutaneous coronary intervention (PCI), and neuroprotective strategies aim to reduce I/R injury severity.

Understanding Ischemia Reperfusion Injury mechanisms is critical for developing targeted therapies to improve clinical outcomes in organ transplantation, cardiovascular disease, and ischemic stroke. Ongoing research explores novel pharmacological and gene therapy approaches to mitigate reperfusion-induced damage.

Request a sample for the Ischemia Reperfusion Injury Market Report @ Ischemia Reperfusion Injury Treatment Market

Ischemia Reperfusion Injury Epidemiology Segmentation:

The Ischemia Reperfusion Injury market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

Total Prevalence of Ischemia Reperfusion Injury
Prevalent Cases of Ischemia Reperfusion Injury by severity
Gender-specific Prevalence of Ischemia Reperfusion Injury
Diagnosed Cases of Episodic and Chronic Ischemia Reperfusion Injury

Download the report to understand which factors are driving Ischemia Reperfusion Injury epidemiology trends @ Ischemia Reperfusion Injury Epidemiological Insights

Ischemia Reperfusion Injury Market

The dynamics of the Ischemia Reperfusion Injury market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as TRO40303, Atorvastatin, and others during the forecasted period 2019-2032.

Ischemia Reperfusion Injury Therapies and Key Companies

atorvastatin: Pfizer
Neu2000KWL group: GNT Pharma
Treprostinil: United Therapeutics
rosiglitazone: GlaxoSmithKline
Bendavia (MTP-131): ICON Clinical Research
Reparixin: Dompé Farmaceutici
(MC-1) Pyridoxal 5′-phosphate: Medicure

To know more about Ischemia Reperfusion Injury treatment, visit @ Ischemia Reperfusion Injury Medications

Scope of the Ischemia Reperfusion Injury Market Report

Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Ischemia Reperfusion Injury Companies:Pfizer, GNT Pharma, United Therapeutics, GlaxoSmithKline, ICON Clinical Research, Dompé Farmaceutici, Medicure, and others
Key Ischemia Reperfusion Injury Therapies: atorvastatin, Neu2000KWL group, Treprostinil, rosiglitazone, Bendavia (MTP-131), Reparixin, (MC-1) Pyridoxal 5′-phosphate, and others
Therapeutic Assessment: Ischemia Reperfusion Injury current marketed and Ischemia Reperfusion Injury emerging therapies
Migraine Market Dynamics: Ischemia Reperfusion Injury market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Ischemia Reperfusion Injury Market Access and Reimbursement

Discover more about therapies set to grab major Ischemia Reperfusion Injury market share @ Ischemia Reperfusion Injury Drugs Market

Table of Contents

1. Ischemia Reperfusion Injury Market Report Introduction

2. Executive Summary for Ischemia Reperfusion Injury

3. SWOT analysis of Ischemia Reperfusion Injury

4. Ischemia Reperfusion Injury Patient Share (%) Overview at a Glance

5. Ischemia Reperfusion Injury Market Overview at a Glance

6. Ischemia Reperfusion Injury Disease Background and Overview

7. Ischemia Reperfusion Injury Epidemiology and Patient Population

8. Country-Specific Patient Population of Ischemia Reperfusion Injury

9. Ischemia Reperfusion Injury Current Treatment and Medical Practices

10. Ischemia Reperfusion Injury Unmet Needs

11. Ischemia Reperfusion Injury Emerging Therapies

12. Ischemia Reperfusion Injury Market Outlook

13. Country-Wise Ischemia Reperfusion Injury Market Analysis (2019-2032)

14. Ischemia Reperfusion Injury Market Access and Reimbursement of Therapies

15. Ischemia Reperfusion Injury Market drivers

16. Ischemia Reperfusion Injury Market barriers

17. Ischemia Reperfusion Injury Appendix

18. Ischemia Reperfusion Injury Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ischemia Reperfusion Injury Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight

Orthopedic Implants Market worth $26.47 billion by 2029

“Stryker Corporation is among the leading companies in the global the company has a strong presence in North America, Europe, the Middle East, Africa, and the Asia Pacific, with its brand presence in more than 75 countries across the globe market.”

The global orthopedic implants market, valued at US$20.13 billion in 2023, is forecasted to grow at a robust CAGR of 4.8%, reaching US$20.94 billion in 2024 and an impressive US$26.47 billion by 2029. Major drivers are the rising prevalence of orthopedic disorders, particularly among the aging population. In addition, strategies adopted by key market players, such as innovative product launches and collaborative efforts, are driving the growth of the market. Additionally, the increasing number of hospitals, disposable income, and access to healthcare services in emerging markets have further fueled the demand for orthopedic implants.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=5230937

The orthopedic implants market is consolidated. As of 2023, the key players operating in the global orthopedic implants market are Zimmer Biomet Holdings, Inc. (US), Stryker Corporation (US), Johnson & Johnson MedTech (US), Smith+Nephew (UK), B.Braun (Germany). In 2023, Zimmer Biomet Holdings, Inc. (US), Stryker Corporation (US), Johnson & Johnson MedTech (US) held a major share of the orthopedic implants market. These players have adopted key strategies such as acquisitions, partnerships, and expansions in the last four to five years.

Stryker Corporation (US)

Stryker Corporation is among the leading companies in the global the company has a strong presence in North America, Europe, the Middle East, Africa, and the Asia Pacific, with its brand presence in more than 75 countries across the globe market. The company has a strong presence in North America, Europe, the Middle East, Africa, and the Asia Pacific, with its brand presence in more than 75 countries across the globe. The company offers orthopedic implants through other Orthopedics & Spine division segment. The company focuses on enhancing its product portfolio and continuous innovation and developing new products to sustain its leading position in the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=5230937

Zimmer Biomet Holdings, Inc. (US)

Zimmer Biomet is a medical device company that develops, manufactures, and markets a wide range of healthcare products. The company offers orthopedic implants through its Knees, Hips, and S.E.T segments. The company has a strong geographic presence across countries such as France, Germany, Italy, Spain, the UK, Switzerland, Japan, Australia, New Zealand, South Korea, China, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. Also, the company has a wide distribution network across Benelux, Nordic, Central & Eastern Europe, and the Middle East & Africa. Zimmer Biomet has a strong brand value among orthopedic implants end users, strong R&D capabilities, and a robust product portfolio.

Johnson & Johnson MedTech (US)

Johnson & Johnson MedTech is another major player operating in the orthopedic implants market. The company is engaged in the R&D, manufacturing, and marketing of orthopedic implants and other healthcare products across the globe. It offers orthopedic implants under the MedTech business segment. The company is dedicated to research & innovation to forge and unveil novel offerings that optimize patient results. The company collaborated with Crossroads Extremity Systems (US) to improve orthopedic care and MedTech devices using new ideas, hoping to give patients better health results. The company holds a significant market share in over 60 nations across diverse territories such as North America, Asia Pacific, Europe, and Africa.

By region, North America is expected to be the largest market by 2029.

The US and Canada accounted for a significant market share in 2023. Several factors, such as the increasing incidence of orthopedic disorders, increasing geriatric and obese populations, increasing road accidents, growing patient preference for minimally invasive procedures, the recent launch of technologically advanced hybrid implants, and increasing awareness among physicians and patients about newly introduced treatment procedures and technologies in the market, are driving the growth of the orthopedic implants market in North America. In the US, about 1.5 million people suffer from osteoporosis. The number of osteoporosis fractures is expected to increase from 1.9 million in 2018 to 3.2 million by 2040 (Source: Amgen). In 2022, more than 1.5 million people in the US have been diagnosed with rheumatoid arthritis (Source: American College of Rheumatology, 2022).

Recent Developments of Orthopedic Implants Market

In September 2024, Stryker (US) acquired osteotomy and ankle truss systems from 4WEB Medical to expand foot and ankle portfolios.

In July 2024, Smith+Nephew (UK) partnered with Healthcare Outcomes Performance Company. This deal focused on offering enhanced solutions for healthcare professionals, patients, and ambulatory surgery centers (ASCs) through the digital and analytics platform of the Healthcare Outcomes Performance Company.

In October 2024, Smith+Nephew (UK) announced that its LEGION Hinged Knee (HK) System is available in the US.

In October 2023, Johnson & Johnson MedTech (US) received 510(K) clearances from the US FDA for its TriLEAP System. It includes a range of specially shaped and standard plates that fit different screw sizes. It also includes tools to reduce, fix, and fuse bones or bone fragments during surgery.

For more information, Inquire Now!

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Orthopedic Implants Market worth $26.47 billion by 2029

Range BJJ Emerges as NYC’s Fastest-Growing Brazilian Jiu-Jitsu Academy, Revolutionizing Martial Arts Training Through Innovative Methodology

New York, NY – February 10, 2025 – In just two years, Range Brazilian Jiu-Jitsu NYC has achieved remarkable growth to become New York City’s fastest-growing Brazilian Jiu-Jitsu (BJJ) academy, transforming the martial arts landscape on the Upper East Side through its systematic, student-centered approach. The academy’s meteoric rise is attributed to its unique methodology that combines traditional BJJ instruction with a meticulously structured curriculum designed for measurable progress and personal development.

“Our unprecedented growth reflects more than just the quality of our instruction—it demonstrates our commitment to each student’s individual journey,” explains Professor Eduardo Capeluto, founder of Range BJJ. “We’ve developed a comprehensive system where students can clearly track their progress, understand their current position, and see their path forward. This transparency, combined with our technical expertise, has resonated strongly with New Yorkers seeking more than just physical training.”

Range BJJ’s innovative curriculum divides training into distinct phases—Fundamentals, Intermediate, and Advanced—each carefully designed to build upon the previous level. The Fundamentals program introduces new students to BJJ’s core principles through 30 foundational classes. The Intermediate program, accessible to students with at least one stripe on their white belt, introduces more complex techniques and sparring opportunities. The Advanced program prepares practitioners for their blue belt through systematic technical development.

“Learning BJJ at Range is similar to mastering a new language,” Professor Capeluto notes. “During the first months, students acquire a basic understanding of fundamental principles and movements. As they progress, they begin implementing techniques in sparring situations, developing not just physical skills but also a tremendous sense of confidence in their ability to defend themselves.”

The academy’s success extends beyond adult programs. Range BJJ’s children’s program, divided into two age brackets, takes a developmentally appropriate approach to teaching martial arts. “We understand that effective youth instruction involves more than just considering size and weight,” explains Professor Capeluto. “The complexity of techniques and how they’re introduced varies significantly based on age and developmental stage.”

As the exclusive Lucas Lepri NYC Association affiliate in New York City, Range BJJ maintains the highest standards of technical instruction. This prestigious affiliation has contributed significantly to the academy’s reputation for excellence and its rapid expansion in the competitive New York martial arts scene.

The academy’s executive program caters to professionals seeking a more personalized approach, offering private instruction that works within their objectives and schedule. All students, regardless of program, receive unlimited access to classes appropriate to their skill level, maximizing opportunities for growth and development.

“What sets Range BJJ apart is our understanding that every student’s journey is unique,” Professor Capeluto emphasizes. “Whether someone joins us for self-defense, physical fitness, or competitive training, our structured approach ensures they can track their progress and achieve their goals systematically.”

The academy’s culture emphasizes respect and sportsmanship, creating an environment where students from all backgrounds feel supported. This inclusive atmosphere has contributed significantly to Range BJJ’s rapid growth and strong community presence in the Upper East Side.

One parent testimonial highlights the academy’s effectiveness: “The instruction at Range BJJ focuses on practical self-defense while maintaining a safe, supportive environment. In a short period, my children has developed not only physical skills but also strategy and confidence in their abilities.”

Brazilian Jiu-Jitsu, considered by many to be the most efficient self-defense martial art, is particularly effective because it addresses the reality that most physical altercations end up at close distance and on the ground. Through sophisticated body positioning, choke holds, and locks, BJJ practitioners can defend themselves and control opponents without requiring strikes, making it an ideal choice for practitioners of all ages and physical capabilities.

Located at 328 E 61st St Ground Floor, New York, NY 10065, Range BJJ continues to welcome new students interested in experiencing their unique approach to Brazilian Jiu-Jitsu. The academy offers a free introductory private class for beginners, providing an opportunity to learn basic concepts and fundamental techniques with undivided instructor attention.

For more information about classes and programs, visit https://www.rangebjj.com/, call (646) 283-1287, or email info@rangebjj.com.

About Range BJJ:

Range BJJ is a premier Brazilian Jiu-Jitsu academy in NYC’s Upper East Side, offering comprehensive martial arts training through a structured, progressive curriculum. As the official Lucas Lepri NYC Association affiliate, the academy combines traditional BJJ techniques with modern teaching methods, emphasizing technical precision and personal development for practitioners of all ages and skill levels.

Media Contact
Company Name: Range Brazilian Jiu-Jitsu NYC
Contact Person: Prof. Eduardo Capeluto
Email: Send Email
Phone: (646) 283-1287
Country: United States
Website: https://www.rangebjj.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Range BJJ Emerges as NYC’s Fastest-Growing Brazilian Jiu-Jitsu Academy, Revolutionizing Martial Arts Training Through Innovative Methodology

Electric Motors Market Share Expected to Reach $206.4 billion by 2029

The global electric motors market share is expected to grow from estimated $152.2 billion in 2024 to $206.4 billion by 2029, at a CAGR of 6.3% during the forecast period.

The global Electric Motors Market share is expected to grow from USD 152.2 billion in 2024 to USD 206.4 billion by 2029, at a CAGR of 6.3% during 2024-2029. As the world population grows and economies expand, the demand for energy, particularly oil and gas, continues to rise. Increasing demand for HVAC (Heating, Ventilation, and Air Conditioning) systems among residential, commercial, and industrial end-users, industries shift towards energy-efficient electric motors due to lowered energy utilization and operational costs in manufacturing industries are some of the major driving factors for the electric motors market.

Due to the growing demand for electric motors within the global automotive, manufacturing, and renewable energy sectors, among others, the electric motor market has bloomed forth globally. All these sectors inherit demanding environments for solving problems and improving reliability. From electric vehicles to industrial machinery, consumer electronics to wind turbines, electric motors find applications in many areas. They not only ensure low energy consumption but also increase efficiency and reduce operating costs.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=717

The growth of the electric vehicle (EV) industry is creating new revenue pockets for the electric motors market due to several factors. Electric motors are the heart of electric vehicles, providing the necessary torque and power to drive the vehicle. The increasing production and adoption of EVs directly boost the demand for electric motors, making the EV industry a significant revenue generator for motor manufacturers.

The electric motors market is experiencing growth due to increased demand for HVAC systems, rising demand for energy-efficient motors, a focus on efficiency and cost reduction, and environmental and regulatory considerations. The rising demand for electric motors causes increasing energy consumption, mostly in emerging markets, which further drives the need for more effective and efficient techniques to meet the demand.

Electric motors are widely used in various end users like Commercial, Industrial, Residential, Transportation, and Agriculture due to high energy efficiency that helps reduce operating costs and energy consumption. Electrical systems are also reliable and require less maintenance than internal combustion engines, making them ideal for many applications. Their versatility also allows them to be used in a variety of systems, from HVAC units and appliances to cars and agricultural machinery.

Regional Analysis

North America is expected to be the second-fastest region in the electric motors market between 2024-2029. The North American market consists of US, Canada, and Mexico. Demand for electric motors in North America is driven by the emerging electric vehicle market, where electric motors are a key part of EV drivetrains. Companies like Tesla, Ford, and General Motors drive this demand to a great extent. Growth factors include increasing demand due to the adoption of energy-efficient motors and the abundance of the electric vehicle industry.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=717

Some of the major players in the electric motors market are ABB (Switzerland), Siemens (Germany), WEG (Brazil), Wolong Electric (China), and NIDEC CORPORATION (Japan).

Siemens

Siemens (Germany) is a technology company and is based out of Germany manufacturing and distributing products and services for transportation, healthcare, and infrastructure markets. The company provides solutions for industries such as automotive manufacturing, cranes, battery manufacturing, commercial buildings, mining, food & beverages, data centers, power utilities wind, oil & gas, and many others. Siemens has the following six operating segments: Digital Industries; Smart Infrastructure; Mobility; Portfolio Companies; Healthineers; and Financial Services. It provides solutions for electric motors under the business segment Digital Industries.

ABB

ABB (Switzerland) undertakes business in power technology and industrial automation through value-added products, systems, solutions, and services that help to enhance productivity, energy efficiency, and power reliability. Some of its products are drives, industrial software, measurement and analytics, PLC automation, robotics, power converters, and inverters, among others. Segments in which ABB operates include Electrification, Motion, Process Automation, and Robotics & Discrete Automation. It provides a diversified product and service portfolio related to electric motors under the Motion business segment.

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar

MarketsandMarkets™ INC.

1615 South Congress Ave.

Suite 103, Delray Beach, FL 33445

USA: +1-888-600-6441

Email: newsletter@marketsandmarkets.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Electric Motors Market Share Expected to Reach $206.4 billion by 2029

Sleep Software Market to Hit USD 1,569.2 Million by 2030 with 10.1% CAGR

“Koninklijke Philips N.V. (Netherlands), Cadwell Industries Inc. (US), COMPUMEDICS LIMITED (Australia), NIHON KOHDEN CORPORATION (Japan), Natus Medical Incorporated (ARCHIMED) (US), Resmed (US)”

Browse 350 market data Tables and 150 Figures spread through 400 Pages and in-depth TOC on “Sleep Software Market by Function (Sleep Tracking, Analysis, Disorder Management, Improvement), Indication (Insomnia, Sleep Apnea), Offering (Platforms, Apps (Mobile)), End-user (Providers, Individual), Deployment, Type, & Region – Global Forecast to 2030

The global sleep software market valued at US$ 776.2 Million in 2023, is forecasted to grow at a robust CAGR of 10.1%, reaching US$ 878.9 Million in 2024 and an impressive US$ 1,569.2 Million by 2030. The market growth is mainly fueled by increased awareness of sleep health and the rising adoption of wearable technologies and AI-based solutions. Consumer-focused applications and healthcare tools are key segments that are driving the market, providing personalized insights and remote monitoring capabilities. Government initiatives encouraging digital health and data privacy compliance by HIPAA and GDPR further impact the growth. The integration of sleep solutions with broader health platforms improves access and propels regional market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2133596

Browse in-depth TOC on “Sleep Software Market“

350 – Tables

150 – Figures

400 – Pages

Integrating telehealth and mHealth solutions drives significant growth in the sleep software market by enhancing accessibility, improving user engagement, and facilitating comprehensive care delivery. Telehealth platforms enable remote consultations with sleep specialists, streamlining diagnosis and treatment pathways, particularly in underserved regions. mHealth applications and wearable devices and smartphones offer real-time sleep tracking, tailored insights, and proven solutions like Cognitive Behavioral Therapy for Insomnia. These advancements position telehealth and mHealth as key enablers in expanding the adoption of sleep software, meeting the growing demand for convenient, data-driven, and scalable solutions in the sleep health industry.

The global sleep software management market is segmented into integrated and standalone softwares, by type. The integrated software type segment accounted for the largest share in 2023. Integrated software holds a significant market share due to its ability to analyze sleep data from interlinked devices with wearables and innovative mattresses, sometimes even IoT. Integrated software brings together data like sleep stages, heart rate, and movement patterns to offer detailed insights and tailored recommendations that help improve sleep quality. This advanced functionality, combined with user-friendly interfaces and compatibility with multiple devices, makes integrated software a preferred choice for both consumers and healthcare providers.

The sleep software market is divided into individual users, healthcare providers, and other end users, by end users. Individual users make up the largest segment of end users in the sleep software market, driven by growing awareness of sleep health and the accessibility of mobile and wearable technologies. People are increasingly turning to sleep software for personalized insights, relaxation techniques, and easy-to-use tracking tools to improve their sleep quality. Affordable pricing models and wide device compatibility make these solutions cater to diverse lifestyles, appealing to individuals seeking convenient and effective ways to enhance their sleep.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=2133596

The key players operating in the sleep software market include Koninklijke Philips N.V. (Netherlands), Cadwell Industries Inc. (US), COMPUMEDICS LIMITED (Australia), Neurovirtual. (US), NIHON KOHDEN CORPORATION (Japan), Nox Medical (Iceland), Natus Medical Incorporated (ARCHIMED) (US), RXNT (US), Resmed (US), Cleveland Medical Devices Inc. (US), SOMNOmedics AG (Germany), CIDELEC (France), Calm (US), Sleep Cycle (Sweden), Headspace Inc. (US), Löwenstein Medical SE & Co. KG (Germany), CamNtech Ltd (United Kingdom), Fisher & Paykel Healthcare Limited. (New Zealand), BioSerenity (France), VYAIRE MEDICAL INC (US), and Inspire Medical Systems, Inc. (US). These companies have adopted organic & inorganic strategies such as product launches, product updates, expansions, partnerships, collaborations, and acquisitions to strengthen their market presence in the sleep software market.

These market players offer a diverse range of products and operate worldwide. They rely on technological advancements to develop innovative products and increase their global footprint. These players focus on acquisitions, collaborations, agreements, mergers, product launches and updates, partnerships, expansions, and other recent developments to expand their global reach and develop innovative sleep solutions.

Koninklijke Philips N.V. (Royal Philips) is the parent company of the Philips Group. It is a multinational medtech company specializing in health technology, offering products and services across healthcare systems, personal health, and consumer electronics. Philips offers various health technology solutions, including systems for image-guided therapy, ultrasound, radiology, hospital patient monitoring, respiratory care, and sleep therapy. They also provide enterprise informatics, consulting, and support services to optimize healthcare delivery. The company operates through four segments: Personal Health, Diagnosis & Treatment, Connected Care, and Others. It provides sleep software through the connected care segment. The Connected Care segment offers integrated solutions across hospital, ambulatory, and home care settings, focusing on patient monitoring, diagnostics, emergency care, sleep and respiratory therapy, and enterprise informatics. Philips Sleep & Respiratory Care offers solutions for sleep apnea, COPD, and respiratory conditions, including diagnostics, therapy, ventilators, and chronic care management in both hospital and home settings. Philips offers a range of sleep software solutions, including DreamMapper for therapy management, Sleepware G3 for sleep study analysis, Care Orchestrator for workflow optimization, EncorePro 2 for CPAP/BiPAP data management, and Actiware for sleep and activity data analysis. These solutions aim to improve patient care and clinical outcomes. Some of its significant subsidiaries include Philips Oral Healthcare, LLC (US), Philips GmbH (Germany), Philips Ultrasound, Inc. (US), and Philips Consumer Lifestyle B.V. (Netherlands). The company operates in North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

ResMed is one of the leading providers of digital health and cloud-connected medical products for sleep apnea. The company develops, manufactures, distributes, and markets medical products for diagnosing, treating, and managing respiratory disorders, especially sleep-disordered breathing (SDB). The company provides diagnostic products, mask systems, headgear, other accessories, dental devices, and cloud-based software informatics solutions. The company operates through two segments: Total Sleep & Respiratory Care and Software as a Service. ResMed offers the myAir app that provides personalized feedback and progress tracking for users of its sleep therapy devices. The app helps optimize CPAP therapy by monitoring device usage, mask fit, and sleep quality. The company has a widespread presence globally in over 140 countries through a network of distributors and a direct sales force spanning North America, Latin America, Europe, the Asia Pacific, and others. ResMed owns subsidiaries such as Brightree LLC, MatrixCare (a cloud-based software company), and Propeller Health (a digital therapeutics company).

For more information, Inquire Now!

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sleep Software Market to Hit USD 1,569.2 Million by 2030 with 10.1% CAGR

Higher max dose guidance for semaglutide offers hope

“When the scale won’t budge, STEP UP! Higher-dose weight loss injections now available.”

A new study increases max-dose guidance for semaglutide. This offers hope for those who didn’t reach their weight goals. The Injection and Infusion Clinic of ABQ now provides higher-dose weight loss injections, backed by the STEP UP trial, which showed 20.7% average weight loss with higher-dose semaglutide. 33.2% of participants lost over 25% of their body weight. Ideal for those who plateaued, this science-backed treatment supports long-term weight management with personalized care.

Albuquerque, NM – Feb 10, 2025 – The Injection and Infusion Clinic of ABQ is excited to announce the availability of new higher-dose weight loss injections as supported by the recent findings of the STEP UP clinical trial. These advanced treatment options are now available to patients in Albuquerque and beyond, offering renewed hope for those who didn’t achieve results previously on the standard doses.

The STEP UP trial, a pivotal 72-week study, demonstrated remarkable outcomes for patients using the higher-dose semaglutide. Participants experienced an average of 20.7% total body weight loss, significantly exceeding the results seen with the standard 2.4 mg dose. This new dosing option is a game-changer for individuals seeking long-term, effective solutions to manage their weight and improve overall health.

“The STEP UP trial results are a major breakthrough in the field of weight loss,” said KC Raver, Clinic Director at The Injection and Infusion Clinic of ABQ. “We’re thrilled to bring this innovative treatment to our patients, especially those who’ve felt stuck in their weight loss journey or haven’t seen success with other methods. These higher doses of semaglutide offer a proven, evidence-based solution to help people achieve their health goals.”

Why Choose Higher-Dose Semaglutide?

Patients who previously didn’t see results or experienced plateaus can now benefit from this enhanced treatment option. Key benefits of the higher-dose semaglutide include:

Greater Weight Loss: Patients in the STEP UP trial achieved an average weight reduction of 20.7% — a significant improvement over standard-dose therapies.
Increased Success: 33.2% of participants on the higher dose lost 25% or more of their body weight, compared to 16.7% with the 2.4 mg dose.
Science-Backed Results: Clinical evidence highlights the safety and effectiveness of this higher dose, offering new hope for patients who felt like they’d exhausted other options.

Semaglutide is a GLP-1 receptor agonist, a class of medications originally developed for diabetes management that has also been shown to support weight loss. These medications work by regulating appetite and glucose metabolism. The findings of the STEP UP study suggest that higher doses may be beneficial for individuals who have plateaued in their weight loss journey or did not achieve desired results with lower doses.

“The results of this study provide additional data on how higher doses of semaglutide may impact weight loss outcomes,” said KC Raver, Clinic Director at The Injection and Infusion Clinic of ABQ. “Offering this option allows us to tailor treatments based on emerging clinical evidence and patient needs.”

The Injection and Infusion Clinic of ABQ integrates evidence-based weight management strategies with individualized patient care. Those interested in learning more about the higher-dose semaglutide treatment can schedule a consultation to discuss their options.

For more information, visit www.infusionclinicabq.com/semaglutide or call 505.445.4300.

About The Injection and Infusion Clinic of ABQ

The Injection and Infusion Clinic of ABQ specializes in weight management and wellness solutions, offering treatments backed by clinical research. With a commitment to personalized care, the clinic empowers patients to achieve lasting health outcomes.

Contact:

The Injection and Infusion Clinic of ABQ

Phone: 505.506.7775

Email: kc@welllifeabq.com

Website: www.infusionclinicabq.com

Media Contact
Company Name: Well Life ABQ
Contact Person: KC Raver
Email: Send Email
Phone: 505-506-7775
Address:8400 Osuna Rd, NE Suite 5C
City: Albuquerque
State: NM
Country: United States
Website: www.welllifeabq.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Higher max dose guidance for semaglutide offers hope

OMyKey: The World’s First NFC Tag with Integrated Fingerprint Authentication

OMyKey: The first NFC tag with fingerprint authentication — offering keyless, biometric-secured access for homes and businesses.

Human Interface introduces OMyKey, a revolutionary NFC tag that integrates fingerprint authentication, bringing a new level of security and convenience to keyless access. Unlike traditional NFC tags or smart key cards, OMyKey requires biometric verification, ensuring only authorized users can gain access. This cutting-edge solution eliminates key duplication risks and strengthens security for homes, businesses, and personal identification.

Revolutionizing Access Control with Biometric Security

OMyKey enhances standard NFC-enabled locks and readers with fingerprint authentication, preventing unauthorized use and increasing peace of mind. Unlike conventional NFC tags, which can be lost, stolen, or copied, OMyKey grants access only after verifying the user’s fingerprint—offering an advanced layer of protection without requiring door lock replacements.

Key Features of OMyKey:

No Door Lock Replacement Required – Works seamlessly with existing NFC-enabled door locks.
Hassle-Free Installation – No complex setup; simply register your fingerprint and use.
Rental-Friendly – Easily transferable without altering existing locks.
Tamper-Proof Design – Internal components break upon unauthorized disassembly.
Single-User Security – Designed for personal use, preventing unauthorized sharing.
Multi-Door Access – One OMyKey can be programmed for multiple locks.
Machine Learning Integration – AI-powered fingerprint recognition adapts and improves over time.
Stops Fingerprint Lifting – Prevents security breaches from traditional fingerprint-copying techniques.

Seamless Integration and Advanced Technology

Built on the ISO/IEC 14443 Type A standard, OMyKey operates at 13.56MHz, making it compatible with most existing RFID reader infrastructures. The Match-On-Card (MOC) technology ensures that fingerprint authentication happens within the tag itself, eliminating security risks from external databases. The onboard 1KB EEPROM memory (768 bytes usable) allows for secure data encoding, enhancing protection for access control, time tracking, and payments.

Beyond Smart Locks: OMyKey’s Versatility

OMyKey is more than just a keyless entry device. Its capabilities extend across industries and use cases, including:

Secure Access Control – Protect sensitive areas with biometric verification.
Time & Attendance Tracking – Monitor employee check-ins without ID cards.
Cashless Transactions – Enable secure, contactless payments.
Personal Identification – Streamline authentication in workplaces and institutions.

Who Benefits from OMyKey?

Tech-Savvy Homeowners – Simplify access control without replacing locks.
Renters – Enjoy keyless security without modifying existing systems.
Families – Ensure access only to trusted individuals.
Small Business Owners – Upgrade security and employee access control.

About Human Interface:

Human Interface, the company behind OMyKey, is dedicated to developing innovative security solutions that address modern vulnerabilities in access control. Bycombiningbiometric authentication with NFC technology, OMyKey eliminates the risks associated with lost keys, stolen access cards, and duplicated NFC tags.

OMyKey is not just a security device—it’s the future of secure, biometric-driven access control. Learn more at www.HI-OMyKey.com.

Media Contact
Company Name: Human Interface
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: www.HI-OMyKey.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: OMyKey: The World’s First NFC Tag with Integrated Fingerprint Authentication